*Coverage requirements and benefits designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies. Medical coverage may require a step edit depending on the plan’s management.

^†SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.

^‡For patients pending insurance approval of their medical benefit for the SKYRIZI IV induction dose.

^§Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI^® (risankizumab-rzaa) for an FDA-approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. For medical coverage, a delay of more than 5 business days or denial of treatment coverage from their insurance will be required. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI^® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

TIM=targeted immunomodulator.